In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models

Y. Jing, J. Zaias, R. Duncan, Stephen J Russell, J. R. Merchan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The urokinase receptor (uPAR) is a clinically relevant target for novel biological therapies. We have previously rescued oncolytic measles viruses fully retargeted against human (MV-h-uPA) or murine (MV-m-uPA) uPAR. Here, we investigated the in vivo effects of systemic administration of MV-m-uPA in immunocompetent cancer models. MV-m-uPA induced in vitro cytotoxicity and replicated in a receptor-dependent manner in murine mammary (4T1) and colon (MC-38 and CT-26) cancer cells. Intravenous administration of MV-m-uPA to 4T1 tumor-bearing mice was not associated with significant clinical or laboratory toxicity. Higher MV-N RNA copy numbers were detected in primary tumors, and viable viral particles were recovered from tumor-bearing tissues only. Non-tumorbearing organs did not show histological signs of viral-induced toxicity. Serum anti-MV antibodies were detected at day 14 of treatment. Immunohistochemistry and immunofluorescence studies confirmed successful tumor targeting and demonstrated enhanced MV-m-uPA-induced tumor cell apoptosis in treated compared with control mice. Significant antitumor effects and prolonged survival were observed after systemic administration of MV-m-uPA in colon (CT-26) and mammary (4T1) cancer models. The above results show safety and feasibility of uPAR targeting by an oncolytic virus, and confirm significant antitumor effects in highly aggressive syngeneic immunocompetent cancer models.

Original languageEnglish (US)
Pages (from-to)289-297
Number of pages9
JournalBritish Dental Journal
Volume217
Issue number1
DOIs
StatePublished - Jul 11 2014

Fingerprint

Oncolytic Viruses
Measles virus
Safety
Neoplasms
Colon
Biological Therapy
Urokinase-Type Plasminogen Activator
Intravenous Administration
Virion
Fluorescent Antibody Technique
Anti-Idiotypic Antibodies
Breast
Immunohistochemistry
RNA
Apoptosis
Breast Neoplasms
Survival

Keywords

  • measles virus
  • syngeneic models
  • tumor targeting
  • urokinase receptor

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models. / Jing, Y.; Zaias, J.; Duncan, R.; Russell, Stephen J; Merchan, J. R.

In: British Dental Journal, Vol. 217, No. 1, 11.07.2014, p. 289-297.

Research output: Contribution to journalArticle

@article{f46a3530b80c4ce8b40aefa19257e8d2,
title = "In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models",
abstract = "The urokinase receptor (uPAR) is a clinically relevant target for novel biological therapies. We have previously rescued oncolytic measles viruses fully retargeted against human (MV-h-uPA) or murine (MV-m-uPA) uPAR. Here, we investigated the in vivo effects of systemic administration of MV-m-uPA in immunocompetent cancer models. MV-m-uPA induced in vitro cytotoxicity and replicated in a receptor-dependent manner in murine mammary (4T1) and colon (MC-38 and CT-26) cancer cells. Intravenous administration of MV-m-uPA to 4T1 tumor-bearing mice was not associated with significant clinical or laboratory toxicity. Higher MV-N RNA copy numbers were detected in primary tumors, and viable viral particles were recovered from tumor-bearing tissues only. Non-tumorbearing organs did not show histological signs of viral-induced toxicity. Serum anti-MV antibodies were detected at day 14 of treatment. Immunohistochemistry and immunofluorescence studies confirmed successful tumor targeting and demonstrated enhanced MV-m-uPA-induced tumor cell apoptosis in treated compared with control mice. Significant antitumor effects and prolonged survival were observed after systemic administration of MV-m-uPA in colon (CT-26) and mammary (4T1) cancer models. The above results show safety and feasibility of uPAR targeting by an oncolytic virus, and confirm significant antitumor effects in highly aggressive syngeneic immunocompetent cancer models.",
keywords = "measles virus, syngeneic models, tumor targeting, urokinase receptor",
author = "Y. Jing and J. Zaias and R. Duncan and Russell, {Stephen J} and Merchan, {J. R.}",
year = "2014",
month = "7",
day = "11",
doi = "10.1038/gt.2013.84",
language = "English (US)",
volume = "217",
pages = "289--297",
journal = "British Dental Journal",
issn = "0007-0610",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models

AU - Jing, Y.

AU - Zaias, J.

AU - Duncan, R.

AU - Russell, Stephen J

AU - Merchan, J. R.

PY - 2014/7/11

Y1 - 2014/7/11

N2 - The urokinase receptor (uPAR) is a clinically relevant target for novel biological therapies. We have previously rescued oncolytic measles viruses fully retargeted against human (MV-h-uPA) or murine (MV-m-uPA) uPAR. Here, we investigated the in vivo effects of systemic administration of MV-m-uPA in immunocompetent cancer models. MV-m-uPA induced in vitro cytotoxicity and replicated in a receptor-dependent manner in murine mammary (4T1) and colon (MC-38 and CT-26) cancer cells. Intravenous administration of MV-m-uPA to 4T1 tumor-bearing mice was not associated with significant clinical or laboratory toxicity. Higher MV-N RNA copy numbers were detected in primary tumors, and viable viral particles were recovered from tumor-bearing tissues only. Non-tumorbearing organs did not show histological signs of viral-induced toxicity. Serum anti-MV antibodies were detected at day 14 of treatment. Immunohistochemistry and immunofluorescence studies confirmed successful tumor targeting and demonstrated enhanced MV-m-uPA-induced tumor cell apoptosis in treated compared with control mice. Significant antitumor effects and prolonged survival were observed after systemic administration of MV-m-uPA in colon (CT-26) and mammary (4T1) cancer models. The above results show safety and feasibility of uPAR targeting by an oncolytic virus, and confirm significant antitumor effects in highly aggressive syngeneic immunocompetent cancer models.

AB - The urokinase receptor (uPAR) is a clinically relevant target for novel biological therapies. We have previously rescued oncolytic measles viruses fully retargeted against human (MV-h-uPA) or murine (MV-m-uPA) uPAR. Here, we investigated the in vivo effects of systemic administration of MV-m-uPA in immunocompetent cancer models. MV-m-uPA induced in vitro cytotoxicity and replicated in a receptor-dependent manner in murine mammary (4T1) and colon (MC-38 and CT-26) cancer cells. Intravenous administration of MV-m-uPA to 4T1 tumor-bearing mice was not associated with significant clinical or laboratory toxicity. Higher MV-N RNA copy numbers were detected in primary tumors, and viable viral particles were recovered from tumor-bearing tissues only. Non-tumorbearing organs did not show histological signs of viral-induced toxicity. Serum anti-MV antibodies were detected at day 14 of treatment. Immunohistochemistry and immunofluorescence studies confirmed successful tumor targeting and demonstrated enhanced MV-m-uPA-induced tumor cell apoptosis in treated compared with control mice. Significant antitumor effects and prolonged survival were observed after systemic administration of MV-m-uPA in colon (CT-26) and mammary (4T1) cancer models. The above results show safety and feasibility of uPAR targeting by an oncolytic virus, and confirm significant antitumor effects in highly aggressive syngeneic immunocompetent cancer models.

KW - measles virus

KW - syngeneic models

KW - tumor targeting

KW - urokinase receptor

UR - http://www.scopus.com/inward/record.url?scp=84908028662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908028662&partnerID=8YFLogxK

U2 - 10.1038/gt.2013.84

DO - 10.1038/gt.2013.84

M3 - Article

C2 - 24430235

AN - SCOPUS:84896717130

VL - 217

SP - 289

EP - 297

JO - British Dental Journal

JF - British Dental Journal

SN - 0007-0610

IS - 1

ER -